Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease
Status:
Withdrawn
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine efficacy of gabapentin vs. placebo at controlling
peripheral neuropathic pain in patients with Fabry disease, and reducing their use of opioid
analgesics. The investigators are conducting a randomized, double-blind, placebo controlled,
single center, cross-over study. The primary endpoint is percent reduction in patients' use
of hydrocodone-acetaminophen.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute